Norliqva (amlodipine) NDC 46287-035

NDC codes

FDA NDC Directory

Product NDC (as listed)46287-035Labeler and product segments. Claims need a package NDC.

Product NDC at billing width46287-0035Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
46287-035-15	46287003515	150 mL in 1 BOTTLE (46287-035-15)Marketed from Apr 15, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Norliqva
Generic name (nonproprietary): amlodipine
Active ingredients: Amlodipine — 1 mg/mL
Dosage form: Solution
Route: Oral
Labeler: CMP Pharma, Inc.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 214439
Marketing start: Apr 15, 2022
Listing expires: Dec 31, 2026
Other FDA classes: Calcium Channel Antagonists (Mechanism)Dihydropyridines (Chemical structure)
Identifiers: Product ID 46287-035_63a6bb49-fb68-4351-be5f-a6b6e8f6b540SPL ID 63a6bb49-fb68-4351-be5f-a6b6e8f6b540SPL set ID c1730a51-4383-4c61-a9a1-7e1326bd0abeRxCUI 2599173, 2599179UNII 1J444QC288
Pharmacologic class: Dihydropyridine Calcium Channel Blocker

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N446287003515 followed by a unit qualifier and the quantity

Package 46287-0035-15. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 28, 2022.

Indications (excerpt from the label)

NORLIQVA is a calcium channel blocker for the treatment of: Hypertension ( 1.1 ) NORLIQVA is indicated for the treatment of hypertension in adults and children 6 years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Coronary Artery Disease ( 1.2 ) Chronic Stable Angina Vasospastic Angina (Prinzmetal's or Variant Angina) Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction <40% 1.1 Hypertension NORLIQVA® is indicated for the treatment of hypertension, to lower blood pressure in adults and children 6 years of age…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 214439

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 214439
Product	Strength	Form · route	Labeler	Product NDC
Norliqvaamlodipine	Amlodipine 1 mg/mL	SolutionOral	CMP Pharma, Inc.	46287-037